Natalizumab - An Insight

Overview:

Natalizumab is a medication used to treat relapsing forms of multiple sclerosis (MS). Multiple sclerosis (MS) is a persistent neurological condition in which the immune system unintentionally targets the protective sheath surrounding nerve fibers, thereby impairing brain-to-body communication.

Numerous symptoms, including exhaustion, trouble walking, tingling or numbness, muscle weakness, and issues with balance and coordination, are observed. It works by inhibiting the movement of immune cells into the brain and spinal cord, helping to reduce the inflammatory damage associated with multiple sclerosis.

The United States Food and Drug Administration (FDA) approved Natalizumab for the treatment of multiple sclerosis on November 23, 2004.

Drug Group:

Monoclonal antibodies are a class of drugs that includes Natalizumab. It is an alpha-4 integrin-targeting humanized IgG4 (immunoglobulin G4) monoclonal antibody. This drug is intended to treat specific autoimmune diseases, including multiple sclerosis and Crohn's disease, by preventing immune cells from penetrating the central nervous system or gastrointestinal tract. By binding to alpha-4 integrins on the surface of these immune cells, Natalizumab reduces inflammation and damage associated with these disorders by blocking the migration of immune cells into inflamed tissues.

Dosages:

Injectable Solution:

• 300 milligrams/15 milliliters.

• Recommended as monotherapy for people with relapsing types of multiple sclerosis, such as active secondary progressive disease, relapsing-remitting MS, and clinically isolated syndrome. 300 mg (milligrams) IV (intravenous) infusion every four weeks.

• When starting and maintaining treatment, consider whether the anticipated benefit outweighs the risk of PML (progressive multifocal leukoencephalopathy).

For Patients:

How Does Natalizumab Work?

Natalizumab is a monoclonal antibody that attaches to α4 integrins on immune cells. By doing this, they prevent these immune cells from migrating to the brain and spinal cord. This helps reduce inflammation associated with disorders like multiple sclerosis (MS) by blocking immune cells from crossing the blood-brain barrier. As a result, the immune system is less likely to attack myelin, the protective covering around nerve fibers.

Although Natalizumab is effective, it does come with some risks, including a rare but serious brain infection called progressive multifocal leukoencephalopathy (PML). For those with certain types of MS, regular monitoring helps control these risks, making it a tailored treatment choice.

How Should Natalizumab Be Used?

A physician or nurse will dilute the concentrated liquid form of Natalizumab before slowly injecting it into a vein. It is typically administered once every four weeks in a licensed infusion facility. It takes approximately sixty minutes for patients to complete the total dosage of Natalizumab.

Serious allergic responses to Natalizumab are possible, and these events can occur at any point during the therapy, although they usually occur two hours following the start of an infusion. The first 12 infusions will need to remain at the infusion center for at least an hour following the completion of the infusion. During this period, patients will be observed by a physician or nurse to determine whether they are experiencing a serious adverse reaction to the medication.

If any unexpected symptoms appear, especially within two hours of the start of the infusion, such as hives, rash, itching, difficulty breathing or swallowing, wheezing, fever, disorientation, chest discomfort, flushing, nausea, or chills, it is important to let the nurse or doctor know immediately. Although Natalizumab helps manage the MS symptoms, it cannot cure the disease completely. Even if the patient feels well, keep all the visits for Natalizumab injections.

What Are the Benefits of Using Natalizumab for Multiple Sclerosis?

• Low Relapse Rates: It has been demonstrated that Natalizumab considerably lowers the frequency of relapses in people with multiple sclerosis.

• Delays the Progression of Impairment: In those with relapsing types of multiple sclerosis, it might help delay the progression of disability.

• Easy Dosage: Administered as a monthly infusion, offering a practical treatment plan.

• Targeted Strategy: Natalizumab targets immune cells primarily implicated in MS inflammation.

• Well-Tolerated: In general, side effects are tolerable and well-tolerated.

• Option for Monotherapy: This may be used alone for maximum effectiveness or in conjunction with other MS drugs.

• Enhances Quality of Life: It can help MS patients lead better lives by reducing the likelihood of relapses and slowing the progression of their disabilities.

What Must the Patient Inform the Doctor Before Taking Natalizumab?

• Infection history, particularly with progressive multifocal leukoencephalopathy (PML).

• Compromised immune system, either recently or in the past.

• Any recent or upcoming vaccinations.

• Allergies to any drugs or ingredients in Natalizumab.

• Pregnancy or the intention to get pregnant.

• Breastfeeding status.

• Additional continuing drugs or therapies.

For Doctors:

Description:

A recombinant humanized IgG4 monoclonal antibody called Natalizumab is made in mouse myeloma cells. In Natalizumab, human framework regions and the areas of a murine antibody determine complementarity and bind to 4-integrin. Natalizumab has a molecular weight of 149 kilodaltons. Natalizumab is a sterile, colorless, transparent, or slightly opalescent concentrate for intravenous infusion.

The following ingredients are present in each 15 ml dose: 300 mg of Natalizumab and 123 mg of sodium chloride. 17.0 mg of monobasic sodium phosphate monohydrate; 7.24 mg of dibasic sodium phosphate heptahydrate (USP); 3.0 mg of polysorbate 80 in USP water for injection (pH 6.1).

Therapeutic Uses of Natalizumab:

Multiple sclerosis (MS) relapse types are treated with Natalizumab. It reduces inflammation by blocking specific immune cells from entering the central nervous system. When previous MS drugs have failed to control the condition, Natalizumab is frequently recommended. It is usually given once a month by intravenous infusion. For MS patients, the medication has demonstrated effectiveness in lowering relapse rates and delaying the course of the illness.

Indications:

Multiple sclerosis (MS) relapse types should be treated with Natalizumab. It is mainly prescribed for MS patients who have not reacted well to previous treatments or who are intolerant to them.

Natalizumab is prescribed as a monotherapy; concurrent use of other immunosuppressive drugs is not advised. Reducing the frequency of clinical exacerbations and delaying the progression of disability in MS patients are the two main objectives of Natalizumab treatment.

It is vital to evaluate the patient's risk of progressive multifocal leukoencephalopathy (PML), an uncommon but dangerous brain infection linked to Natalizumab, before starting the drug.

Dosage Forms and Strengths:

• Form: Intravenously.

• Strength: The injection of Natalizumab is provided as 300 milligrams/20 milligrams per milliliter of the drug in a sterile, single-use vial devoid of preservatives.

Dosage and Administration:

This dosing plan of Natalizumab lowers the risk of relapse for certain patients by modulating the immunological response. However, to avoid cross-infections and adverse effects, it is necessary to observe before administering the drug.

Overdose:

Natalizumab taken beyond 300 mg has to be assessed, as it is not known how much Natalizumab can be given that is safe for the patients.

Missed Dose:

It is advisable to consult your doctor immediately if you have missed a dose of Natalizumab. If the missed dosage is near the next one, it shouldn’t be taken; if it is far from the next dosage, take it at the recommended time. Do not take two doses at once to avoid receiving a double dose. If the person misses the dosage, observe for side effects. Please consult your doctor in all circumstances for further advice.

Who Should Not Receive Natalizumab?

The following are the contraindications of Natalizumab:

• Risk factors or history of progressive multifocal leukoencephalopathy (PML).

• Intolerance to Natalizumab or any ingredient in the mixture.

• Use of immunosuppressants at the moment.

• Those with weakened immune systems.

• Serious diseases that are recent or ongoing

• Severe liver damage.

• Anti-JC virus antibodies are present in some groups because of a higher incidence of PML.

What Are the Precautions and Warnings Regarding Natalizumab?

Several precautions and warnings need to be taken.

These are:

• Risk of Progressive Multifocal Leukoencephalopathy (PML): The use of Natalizumab has been linked to an increased risk of PML, or progressive multifocal leukoencephalopathy, an uncommon and dangerous brain illness. Before beginning therapy, patients are typically tested for JC virus antibodies, as a positive result may increase the risk.

• Immunosuppression: Natalizumab can weaken an individual's defenses against infection.

• Allergic Reactions: Anaphylaxis is a common example of an allergic reaction that some individuals may experience. If these responses take place, immediate medical assistance is required.

• Hypersensitivity: Individuals with a significant hypersensitivity reaction to Natalizumab should refrain from using it.

• Pregnancy and Breastfeeding: The safety of Natalizumab during pregnancy is not well established; therefore, it should only be used if necessary. Breastfeeding while receiving therapy is not advised.

What Are the Side Effects of Natalizumab?

The following are the side effects experienced by several patients:

• Progressive multifocal leukoencephalopathy (PML) is a serious viral brain infection.

• Increased risk of infections, including herpes infections.

• Liver damage.

• Allergic reactions, such as difficulty breathing or swelling.

• Headache, fatigue, and joint pain.

• Nausea, vomiting, and abdominal discomfort.

• Depression and mood changes.

• Elevated blood pressure.

• Infusion-related reactions like fever and chills.

• Rare cases of hypersensitivity reactions.

• Potential for reactivation of latent infections.

• Increased risk of certain cancers with long-term use.

What Are the Pharmacological Aspects of Natalizumab?

Mechanism of action: Natalizumab targets the 4-subunit of 41 and 47 integrins on most leukocytes, inhibiting their adhesion to counter-receptors. This disruption prevents leukocytes from crossing the endothelium into the inflamed tissue. In multiple sclerosis, Natalizumab may block interactions between 41-integrin and VCAM-1, potentially reducing inflammatory cell migration across the blood-brain barrier. Crohn’s disease may inhibit the interaction between 47 integrin and MAdCAM-1, potentially decreasing the recruitment of leukocytes to inflamed gut tissue. Despite these insights, the precise mechanisms of Natalizumab in these conditions remain unclear.

Pharmacokinetics: In patients with multiple sclerosis (MS) receiving a 300 mg dose of Natalizumab through repeated intravenous administration, the average maximum serum concentration was 110 ± 52 mcg/mL. Steady-state trough concentrations ranged from 23 to 29 mcg/mL, with approximately 24 weeks required to reach steady state after every four weeks of dosing. The half-life, volume of distribution, and clearance of Natalizumab were 11 ± 4 days, 5.7 ± 1.9 L, and 16 ± 5 mL/hour, respectively. Body weight and the presence of anti-Natalizumab antibodies were found to influence pharmacokinetics.

For Crohn's disease (CD) patients receiving the same Natalizumab dose, the mean maximum serum concentration was 101 ± 34 mcg/mL. Steady-state trough concentration averaged 10 ± 9 mcg/mL, with an estimated time to steady-state of 16 to 24 weeks. The half-life, volume of distribution, and clearance of Natalizumab were 10 ± 7 days, 5.2 ± 2.8 L, and 22 ± 22 mL/hour, respectively. Body weight, age, gender, race, concurrent medications, and antibodies were studied in these pharmacokinetic studies. There are not enough studies on hepatic insufficiency and renal impairment.

Pharmacodynamics: Natalizumab is a monoclonal antibody medication used primarily for the treatment of Crohn’s disease and multiple sclerosis. They mainly focus on alpha4-integrin and block the immune cells from entering the nervous system. This action stops the transport across the blood-brain barrier, thereby reducing inflammation and damage. The pharmacodynamics include the selective inhibition of lymphocyte cell movement, helping in autoimmune conditions. There is an increased risk of progressive multifocal leukoencephalopathy, a severe brain infection. Therefore, the medication must be used cautiously. Close monitoring and risk-benefit assessments are crucial in its administration, highlighting the delicate balance between therapeutic efficacy and potential adverse effects.

Clinical Studies:

Natalizumab underwent assessment in two double-blind, placebo-controlled trials for multiple sclerosis patients who had experienced at least one relapse in the past year and had an EDSS score between 0 and 5.0. The trials, MS1 and MS2, demonstrated that TYSABRI-treated patients, compared to those on placebo, had a longer time to onset of sustained disability increase. Neurological evaluations were conducted every 12 weeks, with magnetic resonance imaging assessments performed annually. Study MS1 included patients not on interferon-beta or glatiramer acetate for the past six months, while Study MS2 involved patients with relapses on using another drug. The primary endpoint, sustained increase in disability, favored Natalizumab in both studies, showing lower disability increase and annualized relapse rates.

Drug Interactions:

The following are the possible drug interactions of Natalizumab:

• 5-HTP (5-hydroxytryptophan).

• Acetylsalicylic acid.

• Activated charcoal (charcoal).

• Amphetamine / Dextroamphetamine

• Fluticasone / Salmeterol.

• Diphenhydramine / Ibuprofen.

• Naproxen.

• Diphenhydramine / Naproxen.

• Fexofenadine.

• Acetaminophen.

• Dalfampridine.

• Anti-D (RHO) Immunoglobulin (rho (d) immune globulin).

• Multivitamins with minerals.

• Lorazepam.

• Teriflunomide.

• Interferon beta-1a.

• Sulfamethoxazole/Trimethoprim.

• Mupirocin topical.

• Aspirin.

• Olmesartan.

• Celecoxib.

• Gabapentin.

• Omega-3 (Omega-3 polyunsaturated fatty acids).

• Vitamin A topical.

• Methylphenidate.

• Dimethyl fumarate.

• Vitamin D3 (Cholecalciferol).

Use in Specific Populations:

• Pregnancy: Category C pregnancy. When administered at dosages seven times the human dose in guinea pigs, Natalizumab has been demonstrated to decrease pup survival. When administered at levels 2.3 times the human dose in monkeys, Natalizumab has been shown to have hematologic effects on the fetus. More information and carefully researched data on expectant mothers need to be provided. During pregnancy, Natalizumab should only be used if the possible advantages outweigh the risks to the developing fetus.

• Feeding mothers: Natalizumab has been detected in human milk. It is unknown whether infants are affected by this exposure.

• Pediatric use: Natalizumab is not recommended for pediatric patients with multiple sclerosis or Crohn's disease.

• Geriatric use: Not enough participants aged 65 and older were included in the clinical trials of Natalizumab to determine whether their responses differed from those of younger patients. According to other documented clinical experiences, there have been no discernible differences in response between younger and older patients.